PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15223008-1	2004	BACKGROUND/AIMS: Homozygosity for a cysteine to tyrosine translocation at position 282 within the HFE gene (C282Y) is responsible for over 90% of hereditary hemochromatosis (HH) in Celtic populations.	Cysteine	36-44	homeostatic iron regulator	Homo sapiens	98-101	
16871764-2	2006	In recent years, a candidate gene for HLA-linked hemochromatosis, HFE, has been cloned, and a single G-to-A mutation resulting in a cysteine-to-tyrosine substitution (C282Y) has been identified in up to 80% of study patients with type 1 hereditary hemochromatosis.	Cysteine	132-140	homeostatic iron regulator	Homo sapiens	38-69	
14740507-3	2004	Since 80-100% of hemochromatosis patients of European origin are homozygous for a cysteine to tyrosine exchange in the HFE gene at codon 282, genetic screening might be useful.	Cysteine	82-90	homeostatic iron regulator	Homo sapiens	119-122	
15222129-4	2004	The C282Y and the H63D HFE gene distributions in patients with CAD (C282Y: YY 0.6%, CY 9.0%, CC 90.4%; H63D: DD 3.8%, HD 21.8%, HH 74.4%) were not significantly different from those of diabetic subjects without CAD (C282Y: YY 0%, CY 8.2%, CC 91.8%; H63D: DD 2.2%, HD 20.3%, HH 77.5%).	Cysteine	84-86	homeostatic iron regulator	Homo sapiens	23-26	
12208162-3	2002	About 80% of individuals of European descent with HH are homozygous for a cysteine-to-tyrosine substitution (C282Y) in the gene now called HFE.	Cysteine	74-82	homeostatic iron regulator	Homo sapiens	139-142	
9873093-1	1999	A candidate gene, HFE, was recently described in patients with hereditary hemochromatosis (HH) and found to contain a missense mutation leading to a cysteine to tyrosine substitution (C282Y).	Cysteine	149-157	homeostatic iron regulator	Homo sapiens	18-21	
21370159-6	2001	Approximately 85% of unrelated HH patients are homozygous for a point mutation involving a G to A change at nucleotide 845 in the HFE cDNA sequence (G845A) that converts cysteine, at amino acid position 282, to tyrosine (Cys282Tyr or C282Y) (2).	Cysteine	170-178	homeostatic iron regulator	Homo sapiens	130-133	
10739755-10	2000	We conclude that HFE CY and HD heterozygotes differ in iron status from the CC and HH homozygotes and that serum transferrin saturation is more affected than is serum ferritin.	Cysteine	21-23	homeostatic iron regulator	Homo sapiens	17-20	
9356458-3	1997	Most HH patients are homozygous for a Cys-282-->Tyr (C282Y) mutation in HFE gene, which has been shown to disrupt interaction with beta2-microglobulin; a second mutation, His-63-->Asp (H63D), is enriched in HH patients who are heterozygous for C282Y mutation.	Cysteine	38-41	homeostatic iron regulator	Homo sapiens	75-78	
9658732-6	1998	STATE OF ART AND PERSPECTIVE: HC is now recognized as the genetic disease characterized by the homozygosity for the Cys-->Tyr substitution at position 282 (C282Y) of the HFE protein.	Cysteine	116-119	homeostatic iron regulator	Homo sapiens	173-176	
9358014-0	1997	Ethnic differences in the HFE codon 282 (Cys/Tyr) polymorphism.	Cysteine	41-44	homeostatic iron regulator	Homo sapiens	26-29